GET DAILY SIGNALSWhy Is Intuitive Surgical (ISRG) Stock Down -11.24% Today?
Key Takeaways
- ISRG shares plunged 11.24% in Friday's trading session, falling from a previous close of $402.33 to approximately $357.10, following the company's second-quarter earnings release after Thursday's closing bell.
- The primary catalyst was disappointing forward guidance: despite beating Q2 estimates on both revenue and earnings, Intuitive Surgical maintained its full-year 2026 da Vinci procedure growth outlook of 13.5%–15.5% — marking the slowest annual growth rate since 2020.
- U.S. procedure growth decelerated to 12% in Q2, down from 14% in Q1, with management citing Affordable Care Act (ACA) subsidy expirations as a modest headwind weighing on patient procedure volumes.
- A wave of analyst price-target cuts amplified selling pressure, with firms including Citi, JPMorgan, Mizuho, Bernstein, and BTIG all lowering their targets after the report.
- Broader market weakness compounded the decline, as the NASDAQ fell 1.8% and the S&P 500 dropped 0.9%, creating additional headwinds for high-multiple growth names.
- Traders are now watching for stabilization around technical support levels and assessing whether the selloff represents a buying opportunity given the stock's compressed valuation relative to its own five-year history.
Opening Summary
ISRG, the ticker for Intuitive Surgical, Inc. — the global pioneer and dominant force in robotic-assisted surgery best known for its da Vinci surgical platform — suffered one of its steepest single-day declines in years on Friday. Shares tumbled 11.24% to trade near $357.10, erasing roughly $45 in value from Thursday's closing price of $402.33. The selloff was triggered by the company's second-quarter 2026 earnings report, which delivered better-than-expected headline numbers but failed to satisfy investors who fixated on slowing U.S. procedure growth and a full-year outlook that signals deceleration in the company's most closely watched operating metric.
Q2 Earnings: A Beat That Wasn't Enough
At first glance, Intuitive Surgical's Q2 results were strong. The company posted adjusted earnings per share of $2.80, handily surpassing the Wall Street consensus of $2.51. Revenue climbed 19% year-over-year to $2.89 billion, edging past the $2.82 billion analyst forecast. Worldwide procedures across the da Vinci and Ion platforms grew approximately 16%, with Ion procedures surging 36%. The company installed 468 da Vinci surgical systems during the quarter, up from 395 a year earlier, including 246 of the latest da Vinci 5 platform.
Yet investors zeroed in on what management did not do: raise its full-year guidance. Intuitive Surgical reiterated its 2026 da Vinci procedure growth forecast of 13.5% to 15.5%, stating it now expects results to come in near the midpoint of approximately 14.5%. That represents a meaningful slowdown from 17.7% procedure growth achieved in 2025 and marks the slowest expansion pace in six years. For a stock that has long commanded a premium valuation based on sustained high-teens procedure growth, the unchanged — and implicitly conservative — outlook triggered a sharp "sell the news" reaction.
U.S. Procedure Slowdown and ACA Headwinds
A deeper look at the geographic breakdown revealed a concerning trend. U.S. da Vinci procedure growth slowed to 12% in the second quarter, down from 14% in the first quarter. On the earnings call, CEO Dave Rosa acknowledged that "changes in patient coverage and premium dynamics may be affecting when patients seek care and move forward with treatment," pointing to the expiration of enhanced Affordable Care Act premium subsidies as a "modest adverse impact" on domestic procedure volumes.
The ACA headwind rekindled a broader debate across the medtech sector about demand sustainability. Earlier in the week, HCA Healthcare — the largest for-profit U.S. hospital operator — had warned of softer surgical demand and rising numbers of uninsured patients as pandemic-era subsidies expired. While Abbott Laboratories had pushed back against the narrative that ACA enrollment declines were materially affecting the industry, Intuitive Surgical's commentary lent credibility to the concern, especially in deferrable procedure categories where patients may delay care when insurance coverage changes.
Wall Street Slashes Price Targets
The earnings report triggered a barrage of price-target reductions from major Wall Street firms. Citi lowered its target to $500 from $590 and removed ISRG from its "Upside 90-Day Catalyst Watch." JPMorgan cut to $450 from $550, noting that in-line procedures and reiterated guidance overshadowed "healthy" da Vinci placements and "robust" profitability. Mizuho trimmed to $400 from $500, Bernstein to $685 from $750, BTIG to $469 from $512, and Baird to $500 from $525. Most analysts maintained their Buy or Outperform ratings, signaling that the long-term thesis remains intact, but the magnitude of the cuts underscored growing near-term caution.
Broader Market and Valuation Context
The selloff in ISRG did not occur in isolation. The broader market traded lower on Friday, with the tech-heavy NASDAQ falling 1.8% and the S&P 500 slipping 0.9%, creating an unfavorable backdrop for richly valued growth stocks. Intuitive Surgical's valuation had already been under pressure for months — the stock entered the session down roughly 30% from its early-2025 all-time high above $600, with its price-to-earnings ratio compressing from above 95x to approximately 47x. While that P/E remains elevated compared to the broader market and many medtech peers, it sits well below the company's five-year average of 68x, reflecting a significant reset in investor sentiment toward high-multiple names in a risk-off environment. Compounding competitive concerns, new entrants including Medtronic and Johnson & Johnson continue to push into the robotic surgery space, challenging the durability of Intuitive's near-monopoly and pricing power.
Trending AI Robots
In volatile markets like today's, traders increasingly turn to algorithmic and AI-driven strategies to navigate sharp price swings. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. With hundreds of bots covering thousands of tickers — spanning diverse strategies, timeframes, and performance metrics — the platform highlights only those strategies that are currently excelling. For traders seeking to complement their own analysis with data-driven signals during turbulent periods for stocks like ISRG, exploring the Trending AI Robots section offers a window into which automated approaches are navigating the market most effectively right now.
What Comes Next for ISRG
The path forward for Intuitive Surgical hinges on several key factors. First, investors will closely monitor whether U.S. procedure growth stabilizes in the third quarter or continues to face headwinds from insurance coverage shifts. The company's Extended Use program — designed to reduce per-procedure costs for hospitals — could stimulate demand but may also pressure near-term instrument revenue. On the competitive front, the expanding da Vinci 5 installed base and growing Ion adoption provide structural growth levers, though margin impacts from tariffs and leasing mix remain a watchpoint. Intuitive Surgical's next quarterly report will be critical in either validating management's conservative posture or demonstrating that procedure growth can re-accelerate. Until then, the stock is likely to remain sensitive to any macro data or sector commentary that sheds light on U.S. surgical demand trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Aroon Indicator for ISRG shows an upward move is likely
ISRG's Aroon Indicator triggered a bullish signal on October 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 264 similar instances where the Aroon Indicator showed a similar pattern. In 187 of the 264 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 54 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +5.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 210 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 10 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 27%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.670) is normal, around the industry mean (4.942). P/E Ratio (50.439) is within average values for comparable stocks, (37.224). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther
Advertisement